<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669886</url>
  </required_header>
  <id_info>
    <org_study_id>20200234</org_study_id>
    <nct_id>NCT04669886</nct_id>
  </id_info>
  <brief_title>Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.</brief_title>
  <official_title>Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to establish an infectious risk stratification system based on&#xD;
      pre-and post-operative blood endotoxin profile.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants at each endotoxin activity level after surgery.</measure>
    <time_frame>Day 1 (within 30 minutes postoperative)</time_frame>
    <description>The endotoxin activity level assessed from blood samples will be categorized as low (&lt;0.40), intermediate (0.40-0.59) or high (≥0.60) endotoxin activity level. Analysis will be done via Endotoxin Activity Assay (EAA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corelation of endotoxin activity level with post-operative infectious complication</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>infectious complications include fever, and signs and symptoms of systemic inflammatory response syndrome as evaluated by treating physician.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nephrolithiasis</condition>
  <condition>Urosepsis</condition>
  <arm_group>
    <arm_group_label>endotoxin study group</arm_group_label>
    <description>Patients scheduled for Percutaneous Nephrolithotomy (PCNL) as surgical treatment for their kidney stones will be evaluated for postoperative endotoxin levels as a risk marker for sepsis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for PCNL as surgical treatment for their kidney stones at Jackson and&#xD;
        the University of Miami Hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults that is able to consent (≥ 18 years of age)&#xD;
&#xD;
          -  Scheduled to undergo PCNL at Uhealth tower and Jackson Memorial Hospitals&#xD;
&#xD;
          -  not currently immunosuppressed [White blood count (WBC) &gt;= 2, not on immunosuppressive&#xD;
             medications]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable to consent and &lt; 18 years of age&#xD;
&#xD;
          -  currently immunosuppressed (WBC &lt; 2, not on immunosuppressive medications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hemendra N Shah</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hemendra N Shah</last_name>
    <phone>3052433246</phone>
    <email>hns35@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hemendra N Shah, MD</last_name>
      <phone>305-243-3246</phone>
      <email>hns35@miami.edu</email>
    </contact>
    <contact_backup>
      <phone_ext>shah</phone_ext>
      <email>drhemendrashah@yahoo.co.in</email>
    </contact_backup>
    <investigator>
      <last_name>Hemendra N Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Hemendra Shah</investigator_full_name>
    <investigator_title>Associate Professor of clinical Urology</investigator_title>
  </responsible_party>
  <keyword>endotoxin</keyword>
  <keyword>fever</keyword>
  <keyword>infectious complications</keyword>
  <keyword>endourology</keyword>
  <keyword>percutaneous nephrolithotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

